Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT: BG00012 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis
NCT02472938Phase 4Withdrawn
- Sponsor
- Biogen
- Start
- Jul 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing BG00012 with Placebo (2 arms). Primary endpoint: Mean number of cumulative combined unique active (CUA) lesions at 24 weeks. Planned start Jul 2015; status: withdrawn.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02472938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472938.